ABSTRACT
The human placenta is responsible for the adequate supply of nutrients essential for proper embryonic and fetal development such as glucose, amino acids, and lipids. Processes involved in the placental transport of these nutrients are complex and tightly regulated and involve many transporters, receptors, and regulators. In this chapter, we describe the current methods to study the impact of maternal metabolic disorders on key players of human placental transfer of nutrients.
Subject(s)
Lipid Metabolism , Metabolic Diseases/metabolism , Placenta/metabolism , Pregnancy Complications/metabolism , Biological Transport , Blotting, Western/methods , Cholesterol/metabolism , Fatty Acids/metabolism , Female , Food , Humans , Lipoprotein Lipase/metabolism , Metabolic Diseases/complications , Pregnancy , Reverse Transcriptase Polymerase Chain Reaction/methodsABSTRACT
Knowledge of the consequences of maternal obesity in human placental fatty acids (FA) transport and metabolism is limited. Animal studies suggest that placental uptake of maternal FA is altered by maternal overnutrition. We hypothesized that high maternal body mass index (BMI) affects human placental FA transport by modifying expression of key transporters. Full-term placentas were obtained by vaginal delivery from normal weight (BMI, 18.5-24.9 kg/m(2)) and obese (BMI > 30 kg/m(2)) women. Blood samples were collected from the mother at each trimester and from cord blood at delivery. mRNA and protein expression levels were evaluated with real-time RT-PCR and Western blotting. Lipoprotein lipase (LPL) activity was evaluated using enzyme fluorescence. In vitro linoleic acid transport was studied with isolated trophoblasts. Our results demonstrated that maternal obesity is associated with increased placental weight, decreased gestational age, decreased maternal high-density lipoprotein (HDL) levels during the first and third trimesters, increased maternal triglyceride levels during the second and third trimesters, and increased maternal T3 levels during all trimesters, and decreased maternal cholesterol (CHOL) and low-density lipoprotein (LDL) levels during the third trimester; and increased newborn CHOL, LDL, apolipoprotein B100, and T3 levels. Increases in placental CD36 mRNA and protein expression levels, decreased SLC27A4 and FABP1 mRNA and protein and FABP3 protein expression, and increased LPL activity and decreased villus cytotrophoblast linoleic acid transport were also observed. No changes were seen in expression of PPARA, PPARD, or PPARG mRNA and protein. Overall this study demonstrated that maternal obesity impacts placental FA uptake without affecting fetal growth. These changes, however, could modify the fetus metabolism and its predisposition to develop diseases later in life.
